Pharmatek Launches New API Manufacturing Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmatek Launches New API Manufacturing Program



Pharmatek, a contract development and manufacturing organization, has launched a new API-in-capsule manufacturing program. The program is designed to address manufacturing strategies that will lower development cost, shorten timelines, and increase capsule throughput for API-in-capsule productions.

As part of the program, Pharmatek has developed two new cGMP manufacturing suites designed specifically for API-in-capsule productions. The suites include humidity control and inert gas systems, which contribute to a stronger manufacturing process for API-in-capsule productions. In addition, Pharmatek has implemented operational systems to further address efficiencies, including new project teams, updated batch records, extended shift operations, redundant equipment and change parts, and on-demand inventory management.

Source: Pharmatek

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here